Hepatology

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

Reau and Brown discuss new data on MASH/MASLD, including awareness, referral patterns, discussions around alcohol, and emerging pharmacotherapies.

Reau and Brown discuss recent research in hepatitis B, C, and D, including use of statins, GLP-1s, and more.

A pair of hepatology experts discuss the shifting therapeutic landscape in PBC, lingering unmet needs, and where the field may be heading next.

This segment of Liver Lineup features an in-depth discussion on hepatocellular carcinoma screening in patients with cirrhosis.

This segment of Liver Lineup features an in-depth discussion on transplant access with MELD 3.0 and new research about potential disparities it introduces.

Reau and Brown discuss emerging research in liver transplantation and hepatocellular carcinoma from AASLD The Liver Meeting 2025.

Lee describes misconceptions about ALD, the importance of multidisciplinary care, and what the future of pharmacotherapy for this disease may hold.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and other regulatory updates, in this week’s essential news roundup.

The investigational antisense oligonucleotide met the primary endpoint for functional cure rate in the phase 3 B-Well 1 and B-Well 2 trials in chronic hepatitis B.

The Q4 recap for hepatology spotlights new AASLD guidelines, changes to CDC hepatitis B vaccination recommendations, and more.

The designation follows positive phase 2b data and FDA alignment on a phase 3 trial.

Catch up on new infant hepatitis B vaccine recommendations, liver transplant guidelines, research on GLP-1 RAs, and more.

Reau and Brown discuss new data on SGLT2 inhibitors, albumin dosing, AKI risk, and emerging at-home tools for hepatic encephalopathy in cirrhosis.

The 2025 cholangitis year in review covers PBC and PSC advances, FDA designations, trial data, and evolving treatment pathways.

This episode spotlights how advancements in 2025, including data from AASLD 2025, set the stage for future standards of care in cholestatic liver disease.

The hepatology year in review highlights FDA approvals, MASH therapies, viral hepatitis advances, cholestatic disease shifts, and evolving clinical guidance.

The hepatitis year in review covers FDA approvals, HBV and HDV breakthroughs, HCV label expansion, clinical guidelines, and vaccine policy changes.

The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.

Positive topline results from the phase 2b IMPACT trial show statistically significant improvements in key noninvasive tests with pemvidutide.

AASLD and AST have released 2 new guidelines on evaluating adult liver transplant candidates and managing non-graft complications after transplantation.

Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.

Reau and Brown discuss the recent CDC APIC decision to remove the universal birth-dose hepatitis B vaccine for infants born to mothers who test negative for HBV.

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

The 8-3 APIC vote recommends individual-based decision-making for HBV vaccination in infants born to women who test negative for the virus.